Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib

导出原文传递

翻译打印收藏纠错

作者： Lara, Primo N., Jr. ^[1] ; Longmate, Jeff ^[2] ; Mack, Philip C. ^[3] ; Kelly, Karen ^[4] ; Socinski, Mark A. ^[5] ; Salgia, Ravi ; Gitlitz, Barbara ; Li, Tianhong ; Koczywas, Mariana ; Reckamp, Karen L. ; Gandara, David R.

作者单位： USC Norris Comprehens Canc Ctr, Los Angeles, CA USA ^[1] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA ^[2] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA ^[3] City Hope Comprehens Canc Ctr, Duarte, CA USA ^[4] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA ^[5]

发布时间 2017-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Clinical cancer research

2015年21卷19期

4321-4326页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除